Affiliations: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, R5:02, 17176 Stockholm, Sweden
References: Bannon, M.J., The dopamine transporter: Role in neurotoxicity and human disease (2005) Toxicology and Applied Pharmacology, 204 (3), pp. 355-360. , DOI 10.1016/j.taap.2004.08.013, Membrane Transporters in Toxicolog
Darcourt, J., Booij, J., Tatsch, K., EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 (2009) Eur J Nucl Med Mol Imaging, 37, pp. 443-450
Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., Farde, L., Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity (2005) Biological Psychiatry, 57 (3), pp. 229-238. , DOI 10.1016/j.biopsych.2004.11.009, PII S0006322304011679
Erixon-Lindroth, N., Farde, L., Wahlin, T.-B.R., Sovago, J., Halldin, C., Backman, L., The role of the striatal dopamine transporter in cognitive aging (2005) Psychiatry Research - Neuroimaging, 138 (1), pp. 1-12. , DOI 10.1016/j.pscychresns.2004.09.005
Saba, W., Valette, H., Schollhorn-Peyronneau, M.A., [ 11C]LBT-999: A suitable radioligand for investigation of extra-striatal dopamine transporter with PET (2007) Synapse, 61, pp. 17-23
Varrone, A., Steiger, C., Schou, M., In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [ 18F]FE-PE2I, a new dopamine transporter PET radioligand (2009) Synapse, 63, pp. 871-880
Booij, J., De Jong, J., De Bruin, K., Knol, R., De Win, M.M., Van Eck-Smit, B.L., Quantification of striatal dopamine transporters with 123I-FP- CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A doubleblind, placebo-controlled, crossover study in healthy control subjects (2007) J Nucl Med, 48, pp. 359-366
Catafau, A.M., Tolosa, E., Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes (2004) Mov Disord, 19, pp. 1175-1182
Muller, U., Wachter, T., Barthel, H., Reuter, M., Von Cramon, D.Y., Striatal [ 123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease (2000) J Neural Transm, 107, pp. 303-319
McKeith, I., O'Brien, J., Walker, Z., Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study (2007) Lancet Neurol, 6, pp. 305-313
Ponsen, M.M., Stoffers, D., Booij, J., Van Eck-Smit, B.L.F., Wolters, E.C., Berendse, H.W., Idiopathic hyposmia as a preclinical sign of Parkinson's disease (2004) Annals of Neurology, 56 (2), pp. 173-181. , DOI 10.1002/ana.20160
Stiasny-Kolster, K., Doerr, Y., Moller, J.C., Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT (2005) Brain, 128, pp. 126-137
Marek, K., Jennings, D., Can we image premotor Parkinson disease? (2009) Neurology, 72 (7 SUPPL.), pp. S21-S26
Schwarz, J., Storch, A., Koch, W., Pogarell, O., Radau, P.E., Tatsch, K., Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline (2004) Journal of Nuclear Medicine, 45 (10), pp. 1694-1697. , http://jnm.snmjournals.org/cgi/reprint/45/10/1694
Fahn, S., Does levodopa slow or hasten the rate of progression of Parkinson's disease? (2005) J Neurol, 252 (SUPPL. 4), pp. IV37-IV42
Pogarell, O., Koch, W., Gildehaus, F.J., Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts (2006) Eur J Nucl Med Mol Imaging, 33, pp. 407-411
Hesse, S., Strecker, K., Winkler, D., Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up (2008) J Neurol, 255, pp. 1059-1066
Spencer, T.J., Biederman, J., Madras, B.K., Dougherty, D.D., Bonab, A.A., Livni, E., Meltzer, P.C., Fischman, A.J., Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane (2007) Biological Psychiatry, 62 (9), pp. 1059-1061. , DOI 10.1016/j.biopsych.2006.12.008, PII S0006322306015605, Autism and Attention Defecit Hyperactivity Disorder
Hesse, S., Ballaschke, O., Barthel, H., Sabri, O., Dopamine transporter imaging in adult patients with attention-deficit/ hyperactivity disorder (2009) Psychiatry Res, 171, pp. 120-128
Volkow, N.D., Wang, G.J., Kollins, S.H., Evaluating dopamine reward pathway in ADHD: Clinical implications (2009) JAMA, 302, pp. 1084-1091
Bannon, M. J., The dopamine transporter: Role in neurotoxicity and human disease (2005) Toxicology and Applied Pharmacology, 204 (3), pp. 355-360. , DOI 10. 1016/j. taap. 2004. 08. 013, Membrane Transporters in Toxicolog
Catafau, A. M., Tolosa, E., Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes (2004) Mov Disord, 19, pp. 1175-1182
Ponsen, M. M., Stoffers, D., Booij, J., Van Eck-Smit, B. L. F., Wolters, E. C., Berendse, H. W., Idiopathic hyposmia as a preclinical sign of Parkinson's disease (2004) Annals of Neurology, 56 (2), pp. 173-181. , DOI 10. 1002/ana. 20160
Spencer, T. J., Biederman, J., Madras, B. K., Dougherty, D. D., Bonab, A. A., Livni, E., Meltzer, P. C., Fischman, A. J., Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane (2007) Biological Psychiatry, 62 (9), pp. 1059-1061. , DOI 10. 1016/j. biopsych. 2006. 12. 008, PII S0006322306015605, Autism and Attention Defecit Hyperactivity Disorder
Volkow, N. D., Wang, G. J., Kollins, S. H., Evaluating dopamine reward pathway in ADHD: Clinical implications (2009) JAMA, 302, pp. 1084-1091
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(498 views) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 ViewExport to BibTeXExport to EndNote